comprehensive -WSS

comprehensive

author：Wikipedia 2025-09-27 12:35:52 - browse：742

A person walks past the Palantir sign. -- health tech coverage from STAT — FABRICE COFFRINI/AFP via Getty Images

PALO ALTO, Calif. — At a bustling artificial intelligence conference in June hosted by data heavyweight Palantir, a handful of relative newcomers — hospital executives — milled among government and defense industry customers spiritedly trading new uses for the company’s automation and analytics services.

Palantir is best known for its work in government and intelligence, but early adopters of the company’s nascent health offerings, including leaders from Cleveland Clinic, Tampa General Hospital, and HCA, offered demos and gave keynotes last month explaining applications like sepsis monitoring or staff scheduling tools.

For the hospital systems, it’s an expensive bid to tailor the company’s AI technology to hospital operations — and an attempt to blunt the effects of severe staffing shortages and limited bed space amid a resurgence of in-person care.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： BioMarin wins approval for gene therapy to treat hemophilia A
Next article： Study links childhood stress with decline in older age

hotspot

WSS

How medical schools plan to diversify without affirmative action

How medical schools plan to diversify without affirmative action

FDA proposes changes to key medical devices approval pathway

White House touts steps to stem shortages of cancer treatments

FDA approves Sage Therapeutics’ rapid

Regeneron agrees to White House price limits on anti

Wikipedia

comprehensive

entertainment

Walensky prepares to leave CDC — and Congress — behind

How I helped Pfizer think through the ethics of Viagra

DIEP, the 'gold standard' of breast reconstruction, is under threat

New weight loss drugs vying to be the next Wegovy or Mounjaro

New air purifier tech could be key to improving indoor air quality

Group behind ProMed defends move to subscription

Psychedelics group wrestles with new pharma identity

Food makers to regulators: Ultra

As demand for Covid shots wanes, Moderna seeks its next success

FDA scientists endorse Pfizer/BioNTech Covid

focus

How medical schools plan to diversify without affirmative action

FDA scientists endorse Pfizer/BioNTech Covid

Diverse clinical trials: Why aren’t we there yet?

Alnylam reports growth in sales of rare disease treatments

PEPFAR is under serious threat — and so is global health

'Null' research findings aren't empty of meaning. Let's publish them

hotspot

knowledge

hotspot

focus